SecBot SecBot

PLYX

Polaryx Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. WY· CIK 0002075320 Biotech & Drug Discovery
$1.88 +0.06 (+3.30%)
Oct 27 4:00 PM ET · prev $1.82
Market cap
$92.2M
Micro cap
Consensus
Buy
90% Buy or better · 10 analysts
Median target
$7.00
+272% · range $6.00–10.00
Since first trade
−94.6%
from $35.00 · Feb 2
30 days
−7.8%
from $2.04
Range since listing
$1.82–35.00
−95% from high · low Oct 26
Avg volume 20D
29.3K
Oct 8 spike 160.7K
Short interest
118.3K
≈0.2% of shares · −17.5%
Days to cover
3.3
at average volume
Insider net
+$368.0K
2 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
2
analyzed by SecBot
SecBot read MIXED 1 report · latest
Balance 0 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/1
Strongest NEUTRAL Polaryx Therapeutics filed an 8-K setting the date for its 2026 Annual Meeting of Stockholders as September…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    2 insiders bought $368.0K. No open-market sales.

  • InstitutionsMIXED

    Q2 2026: 0 added (0 new), 1 trimmed or exited.

  • AnalystsBULLISH

    9 of 10 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.030 → −$0.048 over 90 days.

  • Short sellersCOVERING

    Short interest −17.5% to 118.3K shares. 3.3 days to cover, ≈0.2% of shares.

  • TrendDOWNTREND

    7% below its 50-day average. New closing low $1.82 on Oct 26.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGNEAR_EXIT1,283$3.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

10 analysts
Buy 90% rate it Buy or better
Strong Buy3Buy6Hold1Sell0Strong Sell0
12-month targets · 4 analysts

Price is below the lowest target. Median implies +272%.Targets as of Oct 28, 2026.

Recent actions
DateFirmActionRating
Aug 13, 2026Raymond James
INITIATE
INITIATEStrong Buy
Jul 27, 2026LUCID CAPITAL MARKETS
INITIATE
INITIATEBuy
Jul 9, 2026HC Wainwright & Co.
INITIATE
INITIATEBuy
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
May 28, 2026
Offering
Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial
PARAMUS, NJ, May 28, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (the “Company” or “Polaryx”) (Nasdaq: PLYX), a clinical-stage biotechnology…
May 14, 2026
Press release
Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards
Company selected as Best Pediatric Lysosomal Storage Disease Therapeutics and Rare Neurodegenerative Disease Drug Development Excellence Award…
Apr 21, 2026
FDA
Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial
Polaryx Therapeutics Receives U.S. FDA Fast Track Designations
Apr 15, 2026
Press release
Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care
Company selected as a Diamond honoree for Excellence in Pediatric Care Company selected as a Diamond honoree for Excellence in Pediatric Care
Apr 1, 2026
Press release
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference
PARAMUS, NJ, April 01, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel…

Insider ledger

Form 4
$368.0K
bought · 2 insiders
$0
sold · 0 insiders
DateInsiderTypeValue
May 27, 2026
Yang Alex Keun Mo
Chief Executive Officer
BUY$360.0K
Feb 18, 2026
Landis G. Michael
Chief Financial Officer
BUY$8.0K

Earnings setup

Estimates
−$0.05
EPS estimate, this quarter
−58%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.05-$0.06–-$0.03+20.8%$0.00
Next Q-$0.06-$0.07–-$0.04+8.3%$0.00
Current FY-$0.20-$0.22–-$0.15+11.4%$0.00
Next FY-$0.29-$0.31–-$0.26-2.7%$0.00

Short side

FINRA· Oct 15, 2026
118,300
shares short
-17.5%
vs prior settlement
3.3
days to cover
≈0.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Jul 17, 2026 SEC
Polaryx Therapeutics filed an 8-K setting the date for its 2026 Annual Meeting of Stockholders as September 10, 2026…
8-K — Impact 2/10
Jun 30, 2026 Inst.
UBS Group AG — NEAR_EXIT
1,283 shares ($3.4K)
May 28, 2026 SEC
Polaryx Therapeutics closed a $10M PIPE financing on May 28, 2026, issuing 2,502,696 shares (~5.3% dilution) at an…
8-K — Impact 5/10
May 28, 2026 Press
Polaryx Therapeutics closed a $10M PIPE financing at ~$4.00/share, issuing 2.5M new shares. Proceeds will fund the…
Impact 6/10
May 28, 2026 Offering
Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial
PARAMUS, NJ, May 28, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (the “Company” or “Polaryx”
May 27, 2026 Insider
Yang Alex Keun Mo bought 88,453 shares
Chief Executive Officer @ $4.07 ($360.0K)
Apr 21, 2026 Press
Polaryx Therapeutics announced that the FDA granted Fast Track Designation (FTD) to its lead candidate PLX-200 for the…
Impact 7/10
Feb 18, 2026 Insider
Landis G. Michael bought 2,867 shares
Chief Financial Officer @ $2.79 ($8.0K)

SecBot reports

2 filings · 3 press releases · 0 bullish · 0 bearish · 2 neutral
All PLYX filing & press-release reports (5)